Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

1.790 -0.020 (-1.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate ↗
Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber... 
Via Benzinga
News headline image
Why Shares of Editas Medicine Are Lower This Morning ↗
Incomplete data is disappointing investors after a long wait. 
Via The Motley Fool
News headline image
Editas Medicine Stock Plunges As CRISPR Gene-Editing Drug Fails To Impress ↗
Editas is working on a treatment for a blindness-causing genetic disorder. 
Via Investor's Business Daily
News headline image
Biotech Playbook Revisited As Technicals Weaken ↗
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
News headline image
'Fast Money Halftime Report' Picks For September 13 ↗
On CNBC's "Fast Money Halftime Report," Shannon Saccocia said Stryker Corporation (NYSE: SYK) has had a really nice run since last year. She sees more upside... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Friday ↗
Wells Fargo lowered the price target on General Motors Company (NYSE: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021 ↗
Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ: 
Via Benzinga
News headline image
3 Red-Hot Healthcare Stocks to Buy in September ↗
These businesses are firing on all cylinders. 
Via The Motley Fool
News headline image
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming ↗
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021 ↗
Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE: 
Via Benzinga
News headline image
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today ↗
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
Via InvestorPlace
News headline image
60 Biggest Movers From Yesterday ↗
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,... 
Via Benzinga
News headline image
35 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value... 
Via Benzinga
News headline image
25 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Greenpro Capital Corp. (NASDAQ: GRNQ) rose 48.7% to $1.13 in pre-market trading. Greenpro Capital shares gained 16% on Friday after the company announced its Angkasa-X... 
Via Benzinga
News headline image
Editas Medicine Unveils Preclinical Data From New Gene Editing Technology ↗
Editas Medicine Inc (NASDAQ: EDIT) announced data on a new gene-editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). Data were... 
Via Benzinga
News headline image
Will Moderna Buy Editas Medicine to Jump Into Gene Editing? ↗
Editas could be an attractive acquisition candidate for the big vaccine maker. 
Via The Motley Fool
News headline image
Why Editas Medicine Beat the Market on Monday ↗
Another analyst ups his recommendation on the stock. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 ↗
Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ: 
Via Benzinga
News headline image
99 Biggest Movers From Yesterday ↗
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
News headline image
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today ↗
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021 ↗
Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ: 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Thursday ↗
Keybanc boosted the price target for HubSpot, Inc. (NYSE: 
Via Benzinga
News headline image
Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript ↗
EDIT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Editas Medicine Stock Shows Improved Relative Strength Rating ↗
A Relative Strength Rating upgrade for Editas Medicine shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
Editas Stock Isn’t Worth Buying This Early Into Treatment Development ↗
EDIT stock is part of a pioneering movement in CRISPR gene editing, but there's no way to know whether the company will succeed long term. 
Via InvestorPlace
News headline image
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week ↗
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains. 
Via The Motley Fool
News headline image
After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding ↗
It's a good time to be a gene-editing company. 
Via The Motley Fool
News headline image
WHO Issues Framework For Governance For Gene Editing Technologies ↗
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or... 
Via Benzinga
News headline image
A Comprehensive Guide To Genomic ETFs ↗
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.